Impact BioMedical (IBO)
Market Price (3/30/2026): $0.5402 | Market Cap: $56.5 MilSector: Health Care | Industry: Biotechnology
Impact BioMedical (IBO)
Market Price (3/30/2026): $0.5402Market Cap: $56.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -140% | Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13341% | ||
| Expensive valuation multiplesP/SPrice/Sales ratio is 1,864x | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 41% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5906%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5906% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 475% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -24% | ||
| High stock price volatilityVol 12M is 402% | ||
| Key risksIBO key risks include [1] a precarious financial position with negative equity and substantial debt, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -140% |
| Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13341% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 1,864x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 41% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5906%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5906% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 475% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -24% |
| High stock price volatilityVol 12M is 402% |
| Key risksIBO key risks include [1] a precarious financial position with negative equity and substantial debt, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Impact BioMedical (IBO) stock has gained about 30% since 11/30/2025 because of the following key factors:
1. Merger Agreement Amendment and Deadline Extension: On February 27, 2026, Impact BioMedical amended its merger and share exchange agreement with Dr Ashleys Limited, extending the end date to July 1, 2026, from the original March 31, 2026. This extension was intended to provide additional time for the fulfillment of closing conditions. The amendment also revised the share structure, with Impact BioMedical poised to receive 169,560,000 PubCo Ordinary Shares, representing 94.20% of the combined company. This development led to a significant increase in the stock price, with shares surging over 115% in pre-market trading on March 5, 2026.
2. Strengthened Financial and Strategic Support from DSS, Inc.: In conjunction with the merger agreement amendment on February 27, 2026, DSS, Inc., which holds approximately 88.87% of IBO on a fully diluted basis, committed to new funding and hold harmless obligations related to the merger. This commitment from DSS, Inc., in exchange for PubCo shares, reinforced its financial and strategic backing for the transaction, aligning the interests of key stakeholders.
Show more
1. Merger Agreement Amendment and Deadline Extension: On February 27, 2026, Impact BioMedical amended its merger and share exchange agreement with Dr Ashleys Limited, extending the end date to July 1, 2026, from the original March 31, 2026. This extension was intended to provide additional time for the fulfillment of closing conditions. The amendment also revised the share structure, with Impact BioMedical poised to receive 169,560,000 PubCo Ordinary Shares, representing 94.20% of the combined company. This development led to a significant increase in the stock price, with shares surging over 115% in pre-market trading on March 5, 2026.
2. Strengthened Financial and Strategic Support from DSS, Inc.: In conjunction with the merger agreement amendment on February 27, 2026, DSS, Inc., which holds approximately 88.87% of IBO on a fully diluted basis, committed to new funding and hold harmless obligations related to the merger. This commitment from DSS, Inc., in exchange for PubCo shares, reinforced its financial and strategic backing for the transaction, aligning the interests of key stakeholders.
Show more
Stock Movement Drivers
Fundamental Drivers
The 28.9% change in IBO stock from 11/30/2025 to 3/29/2026 was primarily driven by a 764.5% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.45 | 0.57 | 28.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 28.0% |
| P/S Multiple | 217.4 | 1,879.3 | 764.5% |
| Shares Outstanding (Mil) | 12 | 105 | -88.4% |
| Cumulative Contribution | 28.9% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| IBO | 28.9% | |
| Market (SPY) | -5.3% | -17.7% |
| Sector (XLV) | -8.7% | -19.3% |
Fundamental Drivers
The -0.8% change in IBO stock from 8/31/2025 to 3/29/2026 was primarily driven by a -88.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.58 | 0.57 | -0.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 357.1% |
| P/S Multiple | 1,009.1 | 1,879.3 | 86.2% |
| Shares Outstanding (Mil) | 12 | 105 | -88.4% |
| Cumulative Contribution | -0.8% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| IBO | -0.8% | |
| Market (SPY) | 0.6% | -11.8% |
| Sector (XLV) | 5.2% | -16.1% |
Fundamental Drivers
The -63.6% change in IBO stock from 2/28/2025 to 3/29/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.58 | 0.57 | -63.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 1,879.3 | |
| Shares Outstanding (Mil) | 12 | 105 | -89.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| IBO | -63.6% | |
| Market (SPY) | 9.8% | -5.2% |
| Sector (XLV) | -2.1% | -7.7% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| IBO | ||
| Market (SPY) | 69.4% | -4.0% |
| Sector (XLV) | 18.4% | -6.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IBO Return | - | - | - | -46% | -65% | 12% | -79% |
| Peers Return | 2% | -0% | -40% | -18% | -49% | -18% | -79% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| IBO Win Rate | - | - | - | 50% | 42% | 33% | |
| Peers Win Rate | 42% | 44% | 30% | 42% | 42% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| IBO Max Drawdown | - | - | - | -57% | -75% | -21% | |
| Peers Max Drawdown | -23% | -39% | -51% | -37% | -67% | -25% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VERU, DARE, PLRX, IXHL, ABBV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
IBO has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to VERU, DARE, PLRX, IXHL, ABBV
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Impact BioMedical (IBO)
Impact Biomedical, Inc. (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. Currently, our operations are conducted, and our assets are owned through our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science (“Impact BioLife”), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. (“Global BioMedical”), which was incorporated on April 18, 2017, and (iv) Sweet Sense, Inc. (“Sweet Sense”), which was incorporated on April 30, 2018. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals and over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. In addition to our existing efforts, we continually search for and evaluate other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty licensing payments. Below is a list of our principal subsidiaries: . Impact BioLife Science, Inc.; . Global Biomedical, Inc.; . Global BioLife, Inc.; and . Sweet Sense, Inc. Impact BioLife Science, Inc. We are the sole owner of the outstanding equity of Impact BioLife Science, Inc. Global Biomedical, Inc. We own 90.9% of Global Biomedical, Inc.’s outstanding equity. Global BioLife, Inc. Through our majority owned subsidiary Global Biomedical, Inc., we own 81.8% of the outstanding equity of Global BioLife, Inc. Sweet Sense, Inc. We are the owner of 95.5% of the outstanding equity of Sweet Sense. Impact BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, Texas.
AI Analysis | Feedback
Here are 1-2 brief analogies for Impact BioMedical (IBO):
- IBO is like a 'scientific invention factory' that patents new drug platforms, sweeteners, and fragrances, then licenses these discoveries to larger companies, similar to how Arm Holdings licenses its chip designs to many manufacturers.
- Think of IBO as a 'discovery engine' for novel ingredients and therapeutic platforms, aiming to license its patented science to pharmaceutical and consumer goods giants, much like a specialized biotech startup develops a drug candidate for a larger pharma partner.
AI Analysis | Feedback
- Universal Therapeutic Drug Platform: A platform focused on discovering and developing therapeutic drugs for neurological, oncology, and immuno-related diseases.
- New Sugar Substitute: A novel sweetening product developed by its subsidiary, Sweet Sense, Inc.
- Multi-use Fragrance: A distinct and versatile fragrance product.
- Intellectual Property Licensing and Partnerships: Offering its patented science and technologies for commercialization by external pharmaceutical and consumer packaged goods companies in exchange for milestone and royalty payments.
AI Analysis | Feedback
Impact BioMedical (IBO) primarily operates as a holding company focused on discovering, confirming, and patenting unique science and technologies. Its business model revolves around collaborating with external partners through licensing, co-development, joint ventures, and other relationships for the commercialization and distribution of its intellectual property.
The company does not name specific major customers. Instead, it identifies the types of companies it seeks to partner with as potential licensors and development partners. These categories of customer companies include:
- Pharmaceutical companies
- Consumer packaged goods (CPG) companies
These partners would commercialize IBIO technologies in exchange for milestone and royalty licensing payments. While the company mentions "direct to consumer wellness offerings," its stated model indicates that these are brought to market through strategic partnerships and licensing arrangements with other companies, rather than through direct sales from IBIO itself to individual consumers.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlFrank D. Heuszel – Chairman & Chief Executive Officer
Mr. Heuszel serves as the Chairman and Chief Executive Officer of Impact BioMedical Inc. He joined DSS, Inc., which is identified as Impact BioMedical's parent company, as CEO in 2019. His background encompasses executive leadership, finance, and strategic planning. Mr. Heuszel holds a Business Administration degree and a J.D., bringing both legal expertise and business acumen to his roles.
Todd D. Macko – Chief Financial Officer, Secretary & Treasurer
Mr. Macko holds the positions of Chief Financial Officer, Secretary, and Treasurer at Impact BioMedical Inc. He has over 25 years of experience in financial management. Mr. Macko became CFO of DSS Inc. in May 2023 and continues to serve in this capacity for Impact BioMedical. His expertise includes financial planning and analysis, business process engineering, and mergers and acquisitions. He is a C.P.A.
Mark J. Suseck – Chief Operating Officer
Mr. Suseck is the Chief Operating Officer of Impact BioMedical Inc., having joined the company in August 2023. Previously, he served as COO of DSS BioHealth Holdings Inc. and as CEO of Vivacitas Oncology Inc. His experience covers company strategy, operations, licensing, acquisitions, and commercialization. Mr. Suseck holds an undergraduate degree in economics and has completed the Executive Management Program at the University of Michigan Business School.
```AI Analysis | Feedback
The key risks for Impact BioMedical (IBO) primarily stem from its business model centered on research and development, intellectual property, and reliance on external partnerships for commercialization.
- High Research & Development (R&D) and Intellectual Property (IP) Commercialization Risk: Impact BioMedical's core business involves discovering, confirming, and patenting unique science and technologies in areas such as a universal therapeutic drug platform, a new sugar substitute, and a multi-use fragrance. This model is inherently risky due to the high costs, long timelines, and uncertainty associated with successful R&D. There is no guarantee that their research will yield viable or patentable technologies, or that any patented IP will be attractive to commercial partners.
- Significant Reliance on External Partnerships for Commercialization: The company's business model explicitly states that it aims to develop new offerings in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. This means Impact BioMedical is heavily dependent on the willingness and ability of pharmaceutical, consumer packaged goods companies, and other potential licensors and development partners to commercialize its technologies. Failure to secure suitable partners or unfavorable terms in such agreements could severely hinder its ability to generate revenue from milestone and royalty payments.
- Early-Stage Company with Undetermined Commercial Success and Revenue Streams: Based on the description, Impact BioMedical primarily focuses on funding research and developing intellectual property, with its subsidiaries being incorporated between 2017 and 2020. The company emphasizes "new offerings" and "advances," suggesting it is in the early stages of bringing products to market. There is no indication of existing commercialized products or established direct sales operations, making its future revenue generation and ultimate commercial success highly uncertain.
AI Analysis | Feedback
null
AI Analysis | Feedback
For Impact BioMedical (IBO), the addressable markets for their main products and services are estimated as follows:
Universal Therapeutic Drug Platform (Biopharmaceuticals, Neurological, Oncology, and Immuno-related Diseases)
- The global biopharmaceutical market size was estimated at USD 537.54 billion in 2025 and is predicted to increase to approximately USD 1,983.73 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 13.95% from 2026 to 2035.
- The global oncology drugs market size was valued at USD 190.10 billion in 2023 and is anticipated to exceed USD 564.50 billion by 2033, growing at a CAGR of 11.50% from 2023 to 2033.
- The global central nervous system (CNS) therapeutics market size was estimated at USD 138.59 billion in 2025 and is projected to reach USD 273.32 billion by 2033, growing at a CAGR of 9.1% from 2026 to 2033.
- The global immunotherapy drugs market size was estimated at USD 285.73 billion in 2025 and is expected to reach USD 675.98 billion by 2033, growing at a CAGR of 11.41% from 2026 to 2033.
New Sugar Substitute
- The global sugar substitutes market size was valued at USD 9.5 billion in 2025 and is projected to grow from USD 10.19 billion in 2026 to USD 20.27 billion by 2034, exhibiting a CAGR of 8.98% during the forecast period.
Multi-use Fragrance
- The global fragrance market size was estimated at USD 58.89 billion in 2025 and is projected to reach USD 89.41 billion by 2033, growing at a CAGR of 5.5% from 2026 to 2033.
AI Analysis | Feedback
Impact BioMedical (IBO) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily stemming from the commercialization of its intellectual property and strategic partnerships. Here are the expected drivers of future revenue growth: * **Licensing and Royalty Payments from its Intellectual Property Portfolio:** Impact BioMedical's core business model revolves around discovering, confirming, and patenting unique science and technologies. With an expanding intellectual property portfolio, including 69 issued patents and over 60 pending patents worldwide (with new allowances for Laetose and 3F in the U.S. and Europe), the company aims to generate revenue through milestone and royalty payments from licensing agreements with external partners. The Laetose and 3F platforms, for instance, are identified as ready for immediate partnering, with the potential to generate licensing and royalty revenue starting in 2025. * **Commercialization of Pipeline Products through Partnerships:** The company is actively developing several proprietary technologies, including Linebacker, Laetose, 3F (Functional Fragrance), and Equivir. These platforms are being advanced for applications in biopharmaceuticals, anti-inflammatory and metabolic diseases, antiviral treatments, and natural insect repellents. Impact BioMedical's strategy involves leveraging partnerships for the development, registration, and commercialization of these product candidates, which is expected to lead to revenue generation. * **Sales from the Recently Acquired Celios Air Purification Technology:** In 2025, Impact BioMedical acquired Celios air purification technology. While initial revenue from Celios in 2025 was modest, this acquisition introduces an existing product line with direct sales potential, focusing on patented filtration solutions to improve indoor air quality. * **Strategic Merger with Dr. Ashleys Limited:** A definitive reverse merger agreement with Dr. Ashleys Limited is in place, with an extended deadline to July 2026. This merger is intended to combine Dr. Ashleys' global pharmaceutical manufacturing capabilities with Impact BioMedical's patent portfolio. This strategic move is expected to provide a more robust infrastructure for the commercialization of Impact BioMedical's technologies, thereby contributing to future revenue growth.AI Analysis | Feedback
Share Issuance
- Impact BioMedical successfully completed its Initial Public Offering (IPO) on September 16, 2024, raising $4.5 million through the issuance of 1.5 million shares at $3.00 per share.
- In 2025, approximately $15,000,000 of principal and interest owed to DSS was converted into 31,939,778 common shares.
- As part of the amended merger agreement with Dr Ashleys Bio Labs Limited in early 2026, the combined entity is set to issue 169,560,000 ordinary shares to Impact BioMedical shareholders, representing 94.20% of the combined company's outstanding shares at closing.
Inbound Investments
- The company raised $4.5 million in capital from its Initial Public Offering (IPO) in September 2024.
Capital Expenditures
- Impact BioMedical, Inc. invested $52,000 in research and development during the third quarter of 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is Impact BioMedical Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to IBO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.82 |
| Mkt Cap | 0.1 |
| Rev LTM | 0 |
| Op Inc LTM | -20 |
| FCF LTM | -14 |
| FCF 3Y Avg | -15 |
| CFO LTM | -14 |
| CFO 3Y Avg | -14 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.6% |
| Rev Chg 3Y Avg | 1,710.6% |
| Rev Chg Q | 10.0% |
| QoQ Delta Rev Chg LTM | 15.3% |
| Op Mgn LTM | -1,315.5% |
| Op Mgn 3Y Avg | -40,338.5% |
| QoQ Delta Op Mgn LTM | 1,306.1% |
| CFO/Rev LTM | -959.6% |
| CFO/Rev 3Y Avg | 8,951.2% |
| FCF/Rev LTM | -1,011.9% |
| FCF/Rev 3Y Avg | 7,480.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 21.5 |
| P/EBIT | -1.1 |
| P/E | -1.2 |
| P/CFO | -1.9 |
| Total Yield | -52.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -61.3% |
| D/E | 0.1 |
| Net D/E | -0.9 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.9% |
| 3M Rtn | -10.6% |
| 6M Rtn | -24.4% |
| 12M Rtn | -52.5% |
| 3Y Rtn | -85.2% |
| 1M Excs Rtn | -0.4% |
| 3M Excs Rtn | -1.3% |
| 6M Excs Rtn | -18.5% |
| 12M Excs Rtn | -64.8% |
| 3Y Excs Rtn | -148.0% |
Price Behavior
Price Behavior
| Market Price | $0.57 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 09/16/2024 | |
| Distance from 52W High | -64.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.50 | $1.05 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 16.0% | -45.2% |
| 3M | 1YR | |
| Volatility | 196.1% | 401.6% |
| Downside Capture | -1.62 | 0.16 |
| Upside Capture | -267.02 | -84.16 |
| Correlation (SPY) | -25.8% | -5.2% |
IBO Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.69 | 0.59 | 0.92 | 0.58 | -1.02 | -0.22 |
| Up Beta | -1.19 | 1.35 | 1.96 | 0.14 | -1.31 | -1.02 |
| Down Beta | 4.19 | 1.11 | 0.99 | 0.79 | -2.31 | 3.08 |
| Up Capture | -19% | -11% | 23% | 1% | -30% | -4% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 20 | 27 | 56 | 110 | 163 |
| Down Capture | 64% | 38% | 42% | 95% | 75% | 63% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 21 | 34 | 68 | 138 | 196 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IBO | |
|---|---|---|---|---|
| IBO | -72.1% | 403.8% | 0.61 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | -10.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | -5.3% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -4.5% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -22.7% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -4.1% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 6.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IBO | |
|---|---|---|---|---|
| IBO | -25.5% | 432.4% | 0.79 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | -6.7% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | -4.1% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -3.6% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -16.0% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | -4.1% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | -0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IBO | |
|---|---|---|---|---|
| IBO | -13.7% | 432.4% | 0.79 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | -6.7% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | -4.1% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -3.6% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -16.0% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | -4.1% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | -0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/11/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 09/17/2024 | 424B4 |
| 03/31/2024 | 06/11/2024 | S-1/A |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 10/05/2023 | 10-Q |
| 03/31/2023 | 08/01/2023 | S-1/A |
| 09/30/2022 | 01/31/2023 | S-1/A |
| 03/31/2022 | 08/24/2022 | S-1/A |
| 06/30/2021 | 09/29/2021 | S-1/A |
| 09/30/2020 | 02/12/2021 | S-1 |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dss,, Inc. | Direct | Sell | 1062026 | 0.55 | 115,600 | 63,476 | 324,202 | Form | |
| 2 | Dss,, Inc. | Direct | Sell | 1062026 | 0.54 | 45,400 | 24,530 | 294,476 | Form | |
| 3 | Dss,, Inc. | Direct | Sell | 5272025 | 0.55 | 115,600 | 63,476 | 24,929 | Form | |
| 4 | Dss,, Inc. | Direct | Sell | 5272025 | 0.54 | 45,400 | Form | |||
| 5 | Dss,, Inc. | Direct | Sell | 4072025 | 0.95 | 890,800 | 845,013 | 152,819 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.